New technologies for retinal therapies

June 19, 2013
New technologies for retinal therapies

The future of the investigation and treatment of retinal disorders is already here at the MedUni Vienna: in the new Christian Doppler "OPTIMA" (Ophthalmic Image Analysis) laboratory headed by Ursula Schmidt-Erfurth, Director of the University Department of Ophthalmology and Optometry, new technologies in optical coherence tomography (OCT) and computer programmes are being developed, which should help to produce the optimal diagnosis and thus, for the first time, completely individual treatment plans.

The best algorithms have been developed by Viennese researchers based on the results of the "View" study conducted worldwide. 2,450 patients were treated under "View" and the data on their retinas examined in the Vienna Reading Center (VRC) of the MedUni Vienna, which functioned as an international analysis platform.

At present further studies are being conducted worldwide and images taken with an even more sophisticated tomography technology sent to the VRC. The CD team at the VRC is developing analysis programmes to enable in future to interrogate tens of thousands of pieces of data within seconds during retinal examinations. "This way the three most important steps are covered at the same time: the right diagnosis, the correct and an adequate check on the treatment. In future we will only treat if it really makes sense and then in a way tailored to fit respective individual needs," says Schmidt-Erfurth. "This is telemedicine of the highest calibre."

At the same time the development of a new optical (OCT) technology is proceeding apace in the "OPTIMA" Christian Doppler laboratory. This is being opened officially on Tuesday, 18 June 2013, and is the eleventh CD laboratory at the MedUni Vienna. According to expert, the next OCT generation and analysis programmes could be operational clinically within two to three years.

Retinal disorders are treated by injecting (anti-) into the eye; this is done in accordance with a recommended strict monthly injection cycle impossible to implement in everyday clinical routine. So far it has not been possible to determine the right point in time for treatment to best suit the individual and the individual course of the disorder – this should be achievable with the assistance of the new technologies from Vienna.

Optical coherence tomography – a development by the MedUni Vienna

OCT is an imaging method, the basic physics of which was developed at the MedUni Vienna in the Centre for Medical Physics and Biomedical Technology, and then developed further and optimized in collaboration with the Eye Clinic for applied use in ophthalmology. With the help of tomography it is possible to identify disorders of the retina in high resolution detail – and to do so at a very early stage: "With this we can look directly into the retinal layers non-invasively and discover the slightest changes early." OCT is an imaging process, which – like ultrasound technology, but without any physical contact whatsoever – can produce high resolution sectional images of biological tissue and which can be regarded as an "optical biopsy". Using this, disorders of the retina such as age-related macular degeneration, diabetes-related disorders or vascular occlusions can be identified before any symptoms appear – and these are then treatable early and in a specifically targeted manner.

Explore further: 200 years of the eye clinic: Diseases of the retina can be predicted

Related Stories

200 years of the eye clinic: Diseases of the retina can be predicted

November 28, 2012
Using optical coherence tomography (OCT), diseases of the retina such as age-related macular degeneration, diabetic retinopathy or vascular occlusions can be predicted before symptoms develop. OCT has been developed in collaboration ...

Functional MRI provides support in operations on the brain

June 14, 2013
Researchers at the MedUni Vienna have proved in a so far unique multicenter study that clinical functional magnetic resonance tomography (fMRI), in the area in which the MedUni Vienna has a leading role internationally, is ...

Breast cancer: New genetic test measures risk of metastases

June 4, 2013
Patients suffering from breast cancer in which the lymph nodes are already affected usually receive prophylactic chemotherapy which sometimes entails many side effects. Scientists at the Comprehensive Cancer Center Vienna ...

New treatment option for brain metastases associated with lung cancer

March 25, 2013
Lung cancer is the world's most common cause of death from cancer. In Austria, around 4,000 people develop this type of cancer every year. One particular problem is the development of brain metastases in association with ...

Recommended for you

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

Too little vitamin D may hinder recovery of injured corneas

July 24, 2017
Injury or disease in combination with too little vitamin D can be bad for the window to your eyes.

Combination of type 2 diabetes and sleep apnoea indicates eyesight loss within four years

July 4, 2017
Research led by the University of Birmingham has discovered that patients who suffer from both Type 2 diabetes and obstructive sleep apnoea are at greater risk of developing a condition that leads to blindness within an average ...

Nearly 60% of pinkeye patients receive antibiotic eye drops, but they're seldom necessary

June 28, 2017
A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment.

Magnetic implants used to treat 'dancing eyes'

June 26, 2017
A research team has successfully used magnets implanted behind a person's eyes to treat nystagmus, a condition characterised by involuntary eye movements.

Drug shows promise against vision-robbing disease in seniors

June 21, 2017
An experimental drug is showing promise against an untreatable eye disease that blinds older adults—and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.